Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.
Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003.
The company aims to treat psychiatric and neurological disorders by preserving the therapeutic benefits of neuroplasticity without inducing a hallucinatory experience.
Read Next
Government
What's Going On With Enveric Biosciences Stock On Friday?
Enveric Biosciences Announces Participation in 2026 BIO International Convention
~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA…
Some analysts argue that, even for competitors, a big clinical trial win for Definium Therapeutics helps validate the psychedelic…
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design…
Eli Lilly's acquisition signals a return of psychedelic drugs for mental health. These compounds offer a new approach to…
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the…
